Su | Mo | Tu | We | Th | Fr | Sa |
---|---|---|---|---|---|---|
Su | Mo | Tu | We | Th | Fr | Sa |
---|---|---|---|---|---|---|
-
May 18, 2021
Late-Breaking Registry Data at EuroPCR Congress Demonstrate Reduced Paravalvular Leak and Low Permanent Pacemaker Rates for the ACURATE neo2™ Aortic Valve System MARLBOROUGH, Mass., May 18, 2021 –
-
Feb 26, 2021
LONDON, UK (26 February 2021) The National Institute for Health and Care Excellence (NICE) has issued guidance recommending the use of TheraSphere™ Y-90 Glass Microspheres for the treatment of...
-
Sep 30, 2020SCS portfolio features full-body MRI conditional devices that combine therapy optionsfor personalized pain relief
MARLBOROUGH, Mass., September 30, 2020 – Boston Scientific (NYSE: BSX) today announced the European launch of the WaveWriter Alpha™ portfolio of Spinal Cord Stimulator (SCS) Systems. The...
-
Sep 28, 2020Next-generation Valve Designed to Reduce Paravalvular Leaking, Improve Procedural Efficiency and Treat More Patients with Expanded Indication over Prior Version
Boston Scientific Corporation (NYSE: BSX) today announced it has initiated a controlled launch of the ACURATE neo2™ Aortic Valve System in Europe. This next-generation transcatheter aortic valve...
-
Sep 10, 2020
Boston Scientific Corporation (NYSE: BSX) announced it has received CE Mark and initiated a limited market release of the fourth generation Vercise Genus™ Deep Brain Stimulation (DBS) System in...
-
Jan 22, 2020
Paris, France., (22 January, 2020) Boston Scientific Corporation (NYSE: BSX) today announced it has completed CE Mark and initiated a limited market release of the EXALT™ Model D Single-Use...
-
Oct 17, 2019Boston Scientific Announces CE Mark Approval of the Vercise™ Neural Navigator 3 Programming Software
Boston Scientific Corporation announced the CE Mark approval of the Vercise™ Neural Navigator 3 directional Deep Brain Stimulation (DBS) programming software - the first system that integrates...
-
Sep 23, 2019
Arnhem (The Netherlands), 23 September 2019 - Awareness of prostate health is alarmingly low in men over 50, a new survey1 commissioned by the European Association of Urology (EAU) has revealed,...
-
Jan 31, 2019System offers multiple non-drug therapies for people with chronic pain
Boston today announced the launch of the Spectra WaveWriter™ Spinal Cord Stimulator (SCS) System in Europe. The Spectra WaveWriter SCS System is the first and only system for the treatment of...
-
Jan 22, 2019
Boston Scientific today announced diabetic subanalysis results from the IMPERIAL trial in which patients treated with the ELUVIA™ Drug-Eluting Vascular Stent System demonstrated statistically...
-
Sep 26, 2018
Boston Scientific Corporation today announced the launch of the GUIDE™ XT System for visualization of Deep Brain Stimulation (DBS) in Europe. The GUIDE XT System is the first DBS visualization...
-
Sep 24, 2018
Arnhem (The Netherlands), 24 September 2018 - Public awareness of urological conditions is alarmingly low throughout Europe. Results of a new international survey of more than 2,500 respondents in...
-
Sep 17, 2018Global BT registry data presented at European Respiratory Society Conference
Boston Scientific today announced positive results from the Bronchial Thermoplasty Global Registry (BTGR) observing patients with severe asthma undergoing treatment with bronchial thermoplasty...
-
Sep 10, 2018Advanced Sealing Technology May Reduce Rates of Paravalvular Leakage
A new study evaluating the safety and performance of the Boston Scientific ACURATE neo2™ Aortic Valve System, a next generation transcatheter aortic valve implantation (TAVI) system,...
-
May 29, 2018The HeartLogic™ Diagnostic is the first and only heart failure diagnostic tool proven to detect 70% of heart failure events several weeks in advance, potentially reducing further hospitalisation for patients with heart failure
Boston Scientific Europe today announced the launch of the HeartLogic™ Heart Failure Diagnostic in Europe. With this launch, the first and only diagnostic tool that enables proactive heart...
-
Mar 28, 2018U.K. Court Affirms that Edwards Lifesciences Infringes Boston Scientific Patent
Boston Scientific Corporation (NYSE: BSX) today announced the U.K. Court of Appeal dismissed Edwards Lifesciences’ appeal and upheld a prior court decision that Edwards’ Sapien 3™ device...
-
May 18, 2017
One-year data from the EWOLUTION registry found that left atrial appendage closure (LAAC) with the WATCHMAN™ device followed by dual antiplatelet therapy (DAPT) significantly reduced the risk of...
-
May 18, 2017
One-year data from the EWOLUTION registry found that left atrial appendage closure (LAAC) with the WATCHMAN™ device followed by dual antiplatelet therapy (DAPT) significantly reduced the risk of...
-
May 16, 2017Acquisition Expands Company’s Structural Heart Portfolio; Increases Offerings for the Treatment of Patients with Valvular Heart Disease
Boston Scientific Corporation (NYSE: BSX) today announced the close of its acquisition of Symetis SA, a privately-held Swiss structural heart company focused on minimally-invasive transcatheter...
-
May 16, 2017
Boston Scientific (NYSE: BSX) today announced positive results from the REPRISE III clinical trial, presented at the annual EuroPCR Scientific Program, in Paris. Data from the study demonstrated...
-
Apr 25, 2017Boston Scientific today announced results from the RANGER SFA trial for the Ranger™ Paclitaxel-Coated PTA Balloon Catheter at the Charing Cross Symposium, in London. Data demonstrated that the drug-coated balloon (DCB) exhibited both a high rate of primary patency and freedom from target lesion revascularization (TLR) at 12 months, reducing the need for re-interventions to re-establish flow in previously blocked blood vessels.
The prospective, randomized, controlled trial, comparing the Ranger DCB to uncoated PTA balloons, included 105 patients with femoropopliteal lesions, at ten centers in Europe. Results demonstrate...
-
Mar 16, 2017Extended battery life of Boston Scientific devices attributed to reduction in replacement procedures and complications; has potential for significant cost savings
Today, the National Institute for Health and Care Excellence (NICE) issued medical technology guidance recommending the use of Boston Scientific Corporation (NYSE: BSX) cardiac resynchronization...
-
Feb 6, 2017
Introducing SmartCRT™ technology, providing MultiSite Pacing with up to 13.3 years battery life.i Boston Scientific Europe today announced the launch of the RESONATE™ cardiac resynchronisation...
-
Oct 13, 2016Boston Scientific has committed to serve as an official Global Partner for the World Thrombosis Day.
A year-long campaign recognized on 13 October, World Thrombosis Day focuses attention on the often overlooked and misunderstood condition of thrombosis. With thousands of educational events in...
-
Sep 19, 2016
Boston Scientific Corporation (NYSE: BSX) has received CE Mark for the LOTUS Edge™ Valve System, the company's next generation transcatheter aortic valve implantation (TAVI) technology. The...